Publications
View AllDesign of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial
LEADER commenced in September 2010, and enrollment concluded in April 2012. There were 9,340 patients enrolled at 410 sites in 32 countries. The mean age of patients was 64.3 ± ...
Changes in liver enzymes and cardiometabolic markers in individuals with obesity and metabolic-dysfunction-associated steatohepatitis treated with semaglutide
In patients with MASH and either overweight or obesity, semaglutide was associated with a clinically and statistically significant reduction in ALT after 6 months of continuous ...
Affiliated Researchers
Institution Info
- Type
- company
- Country
- GB
- Publications
- 3
- Citations
- 1,271
External Links
Identifiers
- ROR
- https://ror.org/0415cr103